TP53 deletion is among the significant factors that determine shorter OS [426] in CLL cases and also correlates with non-response to fludarabine and alkylating agents [423, 427], advance disease [424, 427] and progression of the disease [425]. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.